Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells for Cerebral Palsy
NCT05018819Phase 1Recruiting
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Feb 2022
- Primary completion
- Nov 2027
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of MSV alogénicas in cerebral palsy (CP), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Adverse Events at 48 months. Started Feb 2022; status: recruiting.
02
Drugs
MSV alogénicas
03
Conditions
cerebral palsy (CP)
Beyond the preview
Go deeper on NCT05018819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05018819.